Clostridium difficile associated diarrhea is the most common cause of health-care-associated diarrhea resulting in a spectrum of disease severity ranging from asymptomatic carriage to severe ...
Please provide your email address to receive an email when new articles are posted on . Clostridium difficile shares an important identification with the pediatric population, as this anaerobic ...
Oral metronidazole and vancomycin have been compared to determine if one agent is more efficacious than the other. A prospective, randomized, controlled clinical trial compared metronidazole 250 mg ...
Clostridium difficile is the most common cause of nosocomial diarrhea in acute-care settings. Until now, the two available therapies for C. difficile-associated diarrhea (CDAD), vancomycin and ...
In the past, Clostridium difficile-associated disease (CDAD) was thought of mainly as a nosocomial disease associated with the use of broad-spectrum antibiotics, but its epidemiology seems to be ...
Active ingredient: Fidaxomicin 200 mg; tablets. Indication: For the treatment of Clostridium difficile-associated diarrhea (CDAD). Pharmacology: Fidaxomicin is a fermentation product from the ...
LAS VEGAS — Potentially deadly antibiotic-associated Clostridium difficile-associated diarrhea (CDAD) affects 3 million Americans each year and is increasingly difficult to treat. Clinicians may want ...
TUCSON, Ariz. and AUSTIN, May 2, 2019 -- The Critical Path Institute (C-Path) and CDISC are pleased to announce the release of a global Therapeutic Area Standard, which describes how to use CDISC ...
Stomach acid drugs, known as PPIs (proton pump inhibitors), are linked to a higher risk of diarrhea caused by Clostridium difficile, a type of bacterium. Patients on PPIs who develop persistent ...
Background: Since 2002 an epidemic of Clostridium difficile–associated disease (CDAD) caused by a hypervirulent toxinotype III ribotype 027 strain has spread to many hospitals in Quebec. The strain ...
LEXINGTON, Mass.--(BUSINESS WIRE)-- Cubist Pharmaceuticals, Inc. (NASDAQ: CBST), a leading acute care therapeutics company, today announced positive top-line results from the recently completed Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results